These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9871428)

  • 1. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
    Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
    Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
    Makridakis N; Reichardt JK
    J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
    Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
    J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.
    Stuart JD; Lee FW; Simpson Noel D; Kadwell SH; Overton LK; Hoffman CR; Kost TA; Tippin TK; Yeager RL; Batchelor KW; Bramson HN
    Biochem Pharmacol; 2001 Oct; 62(7):933-42. PubMed ID: 11543729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
    Kolasa A
    Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
    Ko HC; Jusko WJ
    Pharmacotherapy; 1995; 15(4):509-11. PubMed ID: 7479205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
    Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
    Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
    Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
    J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
    Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
    J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actions of 5alpha-reductase inhibitors on the epididymis.
    Robaire B; Henderson NA
    Mol Cell Endocrinol; 2006 May; 250(1-2):190-5. PubMed ID: 16476520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
    Ryu HK; Kim KM; Yoo EA; Sim WY; Chung BC
    Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR.
    Bramson HN; Hermann D; Batchelor KW; Lee FW; James MK; Frye SV
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1496-502. PubMed ID: 9316864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
    Schwartz JI; Van Hecken A; De Schepper PJ; De Lepeleire I; Lasseter KC; Shamblen EC; Winchell GA; Constanzer ML; Chavez CM; Wang DZ; Ebel DL; Justice SJ; Gertz BJ
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2942-7. PubMed ID: 8768856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.
    Amory JK; Page ST; Bremner WJ
    J Androl; 2006; 27(1):72-8. PubMed ID: 16400081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.